Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 24;13:8463–8474. doi: 10.2147/OTT.S258680

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Chen et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Anti-miR-183 sensitized EC cells to cisplatin-induced apoptosis through the FOXO1 pathway. (A) Anti-miR-183 (50 pmol/mL) increased the expression of Bim and Noxa in cisplatin-treated (1 μM) EC9706 and TE-9 cells, whereas the effect of anti-miR-183 was abolished by FOXO1 siRNA (50 pmol/mL). (B) Anti-miR-183 (50 pmol/mL) increased the release of cytochrome c and AIF in cisplatin-treated (1 μM) EC9706 and TE-9 cells, whereas the effect of anti-miR-183 was abolished by FOXO1 siRNA (50 pmol/mL). (C) Anti-miR-183 (50 pmol/mL) enhanced the cleavage of caspase-9 and caspase-3 in cisplatin-treated (1 μM) EC9706 and TE-9 cells, whereas the effect of anti-miR-183 was abolished by FOXO1 siRNA (50 pmol/mL).

Abbreviations: EC, esophageal cancer; FOXO1, Forkhead box O 1; siRNA, small interfering RNA.